Curriculum vitae jan-Åke Gustafsson

Скачать 435.85 Kb.
НазваниеCurriculum vitae jan-Åke Gustafsson
Размер435.85 Kb.
1   2   3   4   5   6   7   8

58. The Molecular Biology of Drug Metabolizing Enzymes, London, December 1986: "Hormonal control of sex specific cytochrome P-450 isozymes in rat liver".

59. UCLA Symposia on Molecular and Cellular Biology: Steroid Hormone Action, Park City, Utah, USA, January 1987: "Structure, function and localization of the glucocorticoid receptor".

60. 2nd Internation Workshop on P450 Gene Regulation, Airlie, Virgina, USA, April 1987: "Cloning and regulation of cytochrome P45015ß and P45016a in rat liver".

61. 7th International Symposium on Microsomes and Drug Oxidations, Adelaide, Australia, August 1987: "Role of endocrine factors in the regulation of cytochrome P-450 expression".

62. 625th meeting of the Biochemistry Society on "Molecular Biology of Hormone Action" Dublin, Irland, September 1987: "Mechanism of Action of Glucocorticoid Hormones".

63. 8th European Winter Conference on Brain Research, Tignes/Val d'Isere, France, March 1988: "On the Expression and Regulation of the Glucocorticoid Receptor".

64. "Glucocorticoids - from cloning to clinic", Edinburgh, England, May 1988.

65. 8th International congress of Endocrinology, Kyoto, Japan, July 1988: "The dioxin and glucocorticoid receptors: two similar gene regulatory proteins".

66. 6th Biophysics-Biochemistry of cytochrome P-450 congress, Vienna, Austria, July 1988: "Glucocorticoid & dioxin receptors - a comparison".

67. Fourth International Symposium on Cellular Endocrinology, Lake Placid, USA, August 1988: "Structure, function and regulation of the glucocorticoid receptor".

68. NATO Advanced Research Workshop on "Molecular Mechanisms and Consequences of Activation of Hormone and Growth Factor Receptors, Nafplion, Greece, September 1988: "Glucocorticoid receptor".

69. Molecular biology in drug design and in drug production, Uppsala, Sweden, December 1988: "Role of ligand binding in glucocorticoid receptor function".

70. 9th International symposium of the Journal of Steroid Biochemistry, Las Palmas, Canary Islands, Spain, May 1989: "Expression and structure of the Glucocorticoid Receptor".

71. Biochemical Society meeting, Host Colloquium on "Development of Mixed-Function Oxidases", Surrey, UK, July 1989: "The cytochromes P-450 of brain and their role in the metabolism of neurosteroids".

72. Molecular Biology and Pathophysiology of Hormone Regulation and Actions, Heidelberg, West Germany, July 1989: "Expression, structure and regulation of the glucocorticoid receptor".

73. FASEB Summer Research Conference: "Nutrients, Gene Expression, and Cancer", Copper Mountain, Colorado, USA, July 1989: "Mechanisms of GH effects on liver cytochrome P-450 isozymes".

74. NATO Advanced Study Institute on "Molecular aspects of monooxygenases and bioactivation of toxic compounds", Cesme, Izmir, Turkey, September 1989: "Hormonal Regulation of P-450 Gene Expression" and "Xenobiotic Regulation of P-450 Gene Expression".

75. Fourth International Symposium in Hematology and Oncology, Stockholm, Sweden, September 1989: "Nutrition and cancer".

76. Steroid Receptors, Transcription Factors, and Gene Expression, San Diego, USA, February 1990: "Mechanisms of steroid nonresponsiveness in mutant cell lines".

77. NORDTOX-90, 1st Nordic Conference of Toxicology and 8th Annual Meeting of Nordic Environmental Mutagen Society, Beito, Norway, March 1990: "Mechanism of dioxin regulation of cytochrome P-450".

78. Berzelius symposium, The Swedish Society of Medicine, Stockholm, Sweden, March 1990: "Ligand-steroid receptor interactions".

79. Scandinavian Physiological Society Meeting, Lund, Sweden, May 1990: "On the use of molecular biology in endocrinology".

80. VIIIth International Symposium Microsomes and Drug Oxidations, Karolinska Institutet, Stockholm, Sweden, June 1990: "Receptor-mediated regulation of gene expression".

81. Eighth international conference on Methods in protein sequence analysis, Kiruna, Sweden, July 1990: "Steroid receptor-DNA interactions".

82. NATO ASI on Biological Signal Transduction, Spetsai, Greece, August 1990: "Steroid Receptors I: General background, steroid structure and metabolism, purification and cloning of steroid receptors, members of the steroid receptor supergene family". "Steroid receptors II: Regulation of expression of the glucocorticoid receptor (GR) gene. Bacterial expression of the DNA binding domain DBDr) of GR. The three-dimensional structure of the DBDr-DNA complex".

83. First Düsseldorf Symposium on Immunotoxicology: Molecular Mechanisms of Dioxin Action on Cell Growth and Differentation, Düsseldorf, Germany, October, 1990: "TCDD receptor: physicochemical characteristics and its significance for toxicological effects".

84. Hepatic Metabolism and Disposition of Endo- and Xenobiotics, Freiburg, Germany, October, 1990: "Comparative Studies of the Glucocorticoid and TCDD-Receptors".

85. Biological Basis For Risk Assessment of Dioxins & Related Compounds, Banbury, USA, October, 1990: "Molecular biology and physiology of TCDD receptor - DNA interactions".

86. Symposium in honour of Professor Minor J. Coon, Ann Arbor, USA, November, 1990: "The glucocorticoid receptor: Structure, function and regulation".

87. Xenobiotics and Cancer: Implications for chemical carcinogenesis and cancer chemotherapy, Tokyo, Japan, November, 1990: "The molecular biology of the glucocorticoid and dioxin receptors".

88. First International symposium on hormonal carcinogenesis, Cancun, Mexico, March, 1991: "Sexual dimorphism of hepatic steroid hormone metabolism and its significance for chemical hepatocarcinogenesis".

89. Cytochrome P450: Advances and prospects, Atlanta, USA, April, 1991: "Regulation of rodent cytochrome P-450 gene expression by steroid hormones".

90. 10th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology, Paris, France, May, 1991: "Glucocorticoid receptor: structural and functional studies".

91. 7th International Conference "Biochemistry & Biophysics of Cytochrome P-450; Structure & Function, Biotechnological & Ecological Aspects", Moscow, U.S.S.R, August 1991: "Molecular mechanisms in regulation of cytochrome P-450 gene expression".

92. 1991 Gordon Conference on Hormone Action, New Hampshire, USA, August, 1991: "Structure and Function of the Three Domains of the Glucocorticoid Receptor".

93. Arolla Workshop 1991 "From Receptor to Gene", Arolla, Switzerland, August, 1991: "Structure and Function of the Three Domains of the Glucocorticoid Receptor".

94. International Symposium on A Molecular View of Steroid Biosynthesis and Metabolism, Jerusalem, Israel, October 1991: "Hepatic steroid metabolism is controlled by the sexually dimorphic pattern of growth hormone secretion in both normal and dwarf rats".

95. European Research Conference on "Mechanism in Toxicity", Klingenthal, Alsace, France, November 1991: "TCDD receptor(s) and their relevance for carcinogenesis".

96. Keystone Symposia on Molecular and Cellular Biology, Steroid/thyroid receptor gene super family, Tamarron, Colorado, USA, February, 1992: "Structural and functional studies on the glucocorticoid receptor".

97. Centre de Recherche du Chul, Québec, Canada, May, 1992: "On the structure and function of the glucocorticoid receptor".

98. Wallenberg Symposium, The Metabolic syndrome, Gothenburg, Sweden, May, 1992: "Mechanism of action of steroid hormones".

99. NOMBA, Progress in Molecular Biology, Helsinki, Finland, May, 1992: "Molecular biology of the glucocorticoid receptor".

100. Endocrine Society Meeting, San Antonio, Texas, USA, June, 1992: "Overexpression in Bacteria, Yeast and Eukaryotic Cells of Steroid Receptors and Steroid Receptor Domains".

101. 9th International Symposium on Microsomes and Drug Oxidations, Jerusalem, Israel, July, 1992: "Mechanisms of regulation of expression of hepatic cytochrome P-450".

102. 5th International congress on Cell Biology, Madrid, Spain, July, 1992: "Functional analysis of the three domains of the glucocorticoid receptor".

103. NATO/FEBS on New Developments in Lipid-Protein Interactions and Receptor Function, Spetsai, Greece, August, 1992: "Determinants for DNA binding site recognition by the glucocorticoid receptor". "Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor".

104. 11th International Conference on Comparative Physiology, The Differences between the sexes, Crans-sur-Sierre, Switzerland, September, 1992: "Why are there male and female livers and kidneys?".

105. The University of Oslo, Jahreföreläsning, Oslo, Norge, September, 1992: "The functional architecture of the glucocorticoid receptor".

106. Keith Harris lecture, Australian Endocrine Society, Adelaide, Australia, October, 1992: "The molecular biology of the glucocorticoid receptor".

107. Invited lecturer at Collége de France, Paris, France, October, 1992: "Functional architecture of the glucocorticoid receptor".

108. Invited lecturer at University of California, Berkeley, USA, October, 1992: "Functional architecture of the glucocorticoid receptor".

109. The Karolinska-Minnesota Frontiers of Medicine Symposium, Minnesota, USA, October, USA, 1992: "Functional architecture of the glucocorticoid receptor".

110. American association for the study of liver diseases, Chicago, Illinois, USA, November, 1992: "Hormonal regulation of Cytochromes P-450".

111. The 23rd International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, Japan, November, 1992: "Induction of cytochrome P450 1A isozymes by heterocyclic amines and other food derived compounds".

112. Functions and structures of genes and proteins, Mariehamn, Åland, November, 1992: "Structure and function of the glucocorticoid receptor".

113. Perspectives in Nutrition Research Towards Year 2000, Oslo, Norway, December 1992: "Molecular Nutrition: Regulation of Gene Expression by Fatty Acids".

114. Receptor Mediated Biological Processes: Implication for Evaluating Carcinogens, Austin, Texas, December 1992.

115. Symposium on Fat and Gene Expression, New Orleans, U.S.A., March, 1993: "Fatty acid activation of the peroxisome proliferator activated receptor (PPAR), a member of the nuclear receptor supergene family".

116. Biochemistry, Endocrinology and Pharmacology of Nuclear Receptors, Marburg, Germany, May, 1993: "Fatty acid activation of PPAR".

117. 11th International Symposium of The Journal of Steroid Biochemistry and Molecular Biology "Recent advances in steroid biochemistry and molecular biology", Seefeld, Austria, May/June, 1993: "Structure and function of the glucocorticoid receptor".

118. The Karolinska Institute and the Summer University of Southern Stockholm, "Understanding Signal Transduction", Stockholm, Sweden, June, 1993: "Steroid/thyroid hormone receptors".

119. 18th International Congress of Chemotherapy, "Principles of endocrine treatment of cancer - basic aspects and clinical regimens", Stockholm, Sweden, June, 1993: "Basic aspects on steroid hormone actions".

120. International Symposium on Antioxidants and Disease Prevention, Biochemical, Nutritional, and Pharmacological Aspects, Stockholm, Sweden June/July, 1993: "Control of Gene Expression by Fatty Acids and Retinoids".

121. 22nd Meeting of the Federation of European Biochemical Societies, Stockholm, Sweden, July, 1993: "The functional architecture of the glucocorticoid receptor".

122. Second Asia-Pacific Symposium on Environmental and Occupational Health - Toxicological Studies, Kobe, Japan, July, 1993: "Mechanisms of Induction of Cytochrome P450 by Environmental Agentsparticipation of Ligand Activated Transcription Factors from Two Different Gene Families".

123. 5th International CBT Symposium, "Intracellular hormone receptors and ligand-dependent transcriptional regulation", Stockholm, Sweden, September, 1993: "Activation of PPAR by fatty acids".

124. Instituto Juan March de Estudios e investigaciones, Centre for International Meetings on Biology. Workshop on Neuroendocrinology of Growth. Madrid, Spain, October, 1993: "Mechanisms of sex differentiation and growth hormone regulation of hepatic P450 genes in the rat".

125. 8th International Conference on Cytochrome P450, Lisbon, Portugal, October, 1993: "Mechansims of sex differentiation and growth hormone regulation of hepatic P450 genes in the rat".

126. 4th International Thyroid Symposium on "Genetic defects of thyroid and steroid hormons receptors: molecular basis and clinical expression", Ulm, Germany, November, 1993: "Thyroid and steroid hormone receptor family".

127. Biochemical Society Meeting 649, London, U.K., December, 1993: "Receptor-mediated regulation of drug metabolising enzymes".

128. Norsk Biokjemisk Selskaps 30 årsjubileumsmöte, January, 1994: "Novel aspects on ligand activated transcription factors".

129. Keystone Symposia on Molecular and Cellular Biology, Taos, New Mexico, February, 1994: "The dioxin receptor - another ligand activated transcription factor".

130. Symposium on Eukaryotic Gene Expression and Regulating Signals, New York, April, 1994: "Functional architecture of the glucocorticoid receptor and characteristics of some novel members of the steroid/thyroid hormone receptor super family".

131. The Lundberg Symposium, Gothenburg, May, 1994: "Nuclear receptors - an expanding super gene family".

132. Nordic Meeting on Biochemical and Medical Aspects of Lipid Metabolism in Peroxisomes and Mitochondria, Huddinge, Sweden, May, 1994: "Activation of the PPAR".

133. The First International Conference on Steroids and Bone, Florence, Italy, May, 1994: "The functional architecture of the glucocorticoid receptor".

134. United European Gastroenterology week June 25-29, 1994, Oslo, Norway: "Fatty acid control of gene expression via a member of the nuclear receptor supergene family (PPAR)".

135. XIIth International Congress of Pharmacology, Montréal, Québec, Canada, July, 1994: "Fatty acid activation of PPAR".

136. 10th International Symposium on Microsomes & Drug Oxidations, Toronto, Canada, July, 1994: "Functional analysis of flanking sequences of sex-specific P-450 genes expressed in rat liver".

137. Second International Symposium on Hormonal Carcinogenesis, Novum, Stockholm, July, 1994: "Novel Aspects on Ligand Activated Transcription Factors in Control of Cytochrome P-450".

138. NATO Advanced Study Institute on Molecular Mechansims of Transcellular Signaling: "From the Membrane to the Gene", Spetsai, Greece, August, 1994: "Recent developments in the field of the nuclear receptor supergene family" and "The dioxin receptor - another ligand activated transcription factor".

139. University of Wisconsin-Madison: "Steroid Receptor Superfamily Symposium", Madison, USA, September, 1994: "Functional analysis of the glucocorticoid receptor".

140. IX International Congress on Hormonal Steroids. Dallas, Texas, USA, September, 1994: "Activation of the PPAR".

141. Health Research in Quebec and the world: today and tomorrow: Montréal, Canada, October, 1994: "University-Industry Partnership in Sweden".

142. Worcester Foundation for Experimental Biology, Gregory Pincus Lecture, Shrewsbury, MA, USA, November, 1994: ”Functional organization of the glucocorticoid receptor”.

143. Symposium on "Bridging Basic Science and Liver Disease". Boston, USA, November, 1994: "Mechanisms of growth hormone regulation of sexually differentiated gene expression in the liver".

144. Receptor Mediated Mechanisms in Carcinogenesis, Lyon, France, November, 1994: "Nuclear Receptors and Chemical Carcinogenesis".

145. Keystone Symposia conference on ”Molecular Toxicology”, Keystone, USA, January, 1995: ”Functional architecture of the dioxin receptor/arnt heterodi-mer”.

146. An AACR Special Conference in Cancer Research: ”Mechanism of action of retinoids, vitamin D, and steroid hormones”, Whistler, British Columbia, Canada, January, 1995: ”Mechanisms of activation and action of PPAR (Peroxisome Proliferator Activated Receptor).

147. Sterling lecture, University of Pennsylvania, Philadelphia, USA, March, 1995: Mechanism of action of the glucocorticoid receptor and of the peroxisome proliferatoractivated receptor (PPAR).

148. EMBO Workshop; Structure and Function of Steroid and Nuclear Receptors, Alghero, Sardinia, Italy, April, 1995: ”Transcriptional activation by the glucocorticoid receptor: Role of the 1 domain”.

149. Pharmacology & Toxicology 50th Anniversary Symposium, Perspectives in the development and safety of new medicines: Biological diversity and structure specificity, Copenhagen, Denmark, May, 1995: ”Mechanisms of Regulation of Drug Metabolizing Enzymes”.

150. 12th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology. ”Recent Advances in Steroid Biochemistry and Molecular Biology”, Berlin, Germany, May, 1995: ”Functional Analysis of the glucocorticoid receptor”.

151. The Aspen Institute: Peroxisomes: Biology and Role in Toxicology and Disease, Aspen, USA, June/July 1995: ”Fatty acid signalling of peroxisome proliferator-activated receptor”.

152. VII International Congress of Toxicology, Seattle, USA, July, 1995: ”Receptor-mediated toxicity”.

153. Gordon Research Conference on Hormone Action, New Hampshire, USA, July/August, 1995: ”Functional organization of the dioxin receptor-Arnt complex”.

154. The Rank Prize Funds, Mini-Symposium on Nutrients as Regulators (Nutrient Sensing), Grasmere, England, September, 1995: “Regulation of gene expression by fatty acids”.

155. 7th International CBT Symposium: Nuclear Orphan Receptors: Novel Regulators in Physiology and Pathology, NOVUM, Sweden, September, 1995: ”Mechanism of signal transduction of PPAR”.

156. International Symposium on ”DHEA Transformation into Androgens and Estrogens in Target Tissues: Intracrinology”, Québec, Canada, September, 1995: ”Activation of peroxisome proliferator activated receptor (PPAR)”.

157. The European Respiratory Society Annual Congress, Barcelona, Spain, September, 1995: ”Glucocorticoid receptor and transcription factor interactions”.

158. International Symposium on Control Mechanisms of Carcinogenesis, Mainz, Germany, September, 1995: ”Ligand activated transcription factors”.

159. The British Biochemical Society Meeting No. 657, Aberdeen, U.K., December, 1995: ”Control of gene expression by fatty acids: Role of the peroxisome proliferator activated receptor (PPAR)”.

160. From Invention to Business in Biotechnology, Helsinki, Finland, January, 1996: ”Future scenarios for Biocenters”.

161. Keystone Symposia on Molecular and Cellular Biology, Steroid/Thyroid/Retinoic Acid Gene Family, Lake Tahoe, California, March, 1996: “Cloning of a novel estrogen receptor (ER)”.

162. 2nd Oulu Symposium on Molecular Approaches to Reproductive Health, Oulu, Finland, May, 1996: “Orphan receptors and the search for endogenous ligands”.

163. International Society for Endocrinology, San Francisco, USA, June, 1996: ”Negative cross-talk between the glucocorticoid receptor and other signal transduction pathways”.

164. NATO/FEBS Advanced Study Institute, International Summer School on Molecular Mechanisms of Signaling and Targeting, Spetsai, Greece, August, 1996: ”Orphan nuclear receptors - an exciting development of the steroid/thyroid hormone receptor field” and ”Growth hormone as determinant of hepatic sexual dimorphism”.

165. Estrogen and the Blood Vessel Wall Symposium, Seattle, Washington, USA, September, 1996: ”Cloning, Expression and Function of a Novel Estrogen Receptor”.

166. KBF-Symposium Molecuar Targets for Drug Development, Braunschweig, Germany, September, 1996: ”Steroid receptors as molecular targets for drug development”.

167. SPBBM, Colloque GERMÉ, PPARs, nutriments and xenobiotics: as mediators of cell regulation? Dijon, France, September, 1996: “Regulation of PPAR by glucocor-ticoids and nor-epinephrine”.

168. Tore Nilson symposium on ”Aspects of hormonal regulation of artherosclerosis”, Stockholm, September, 1996: ”Fatty acids and gene regulation”.

169. Steroid Receptor Superfamily Symposium, Madison, USA, September, 1996: ”Characteristics and function of the novel estrogen receptor ”.

170. Deutsche Forschungsgemeinschaft, Symposium Hormonally Active Agents in Food, Kaiserslautern, Germany, October, 1996: ”Novel aspects of environmentally and dietary related ligand activated transcription factors”.

171. University of Leicester, MRC Toxicology Unit, Leicester, U.K., February, 1997: ”What new can we learn about estrogens in light of the discovery of the novel estrogen receptor ”.

172. Workshop on ”Universities in the Cross-Streams of Globalisation and Information Technology”, Italy, February, 1997: ”Government - Industry - University interaction”.

173. 31st International Meeting of the European Society for Clinical Investigation (ESCI), Kiel, Germany, March, 1997: “Functional characteristics of estrogen receptor ”.

174. NIH, Bethesda, USA, April, 1997: “Recent insights into mechanisms of glucocor-ticoid action - new crosstalk and coactivators”.

175. Mechanisms of action of estrogens and physiological needs, Chantilly, France, April, 1997: “ and  estradiol receptors”.

176. Frontiers in Estrogen Action, Key West, USA, May, 1997: “Identification and characterization of ER”.

177. The paradoxes of growth hormone action, Fiskeb㄰〰5454kil, Sweden, May, 1997: “Free fatty acids - mediators of GH action”.

178. The Endocrine Society 79th Annual Meeting, ENDO ‘97, Minneapolis, USA, June, 1997: ER: a new isoform of the estrogen receptor”.

179. 1997 Marabou symposium: Diet and genetic interactions, Stockholm, Sweden, June, 1997: “Fatty acids and gene expression”.

180. Paediatric Endocrinology 1997, Joint Meeting of ESPE and LWPES, in collabora-tion with APEG, JSPE and SLEP, Stockholm, Sweden, June, 1997: “Cloning and function of the novel estrogen receptor ”.

181. Eurotox Congress in collaboration with the Danish Society of Pharmacology and Toxicology, Aarhus, Denmark, June, 1997: “Receptor mediated toxic responses”.

182. FEBS Special Meeting, Cell Signalling Mechanisms; from membrane to nucleus, Amsterdam, The Netherlands, June/July, 1997: “Novel insights into estrogen mechanism of action”.

183. XXXIII International Congress of Physiological Sciences IUPS 1997, St. Petersburg, Russia, July, 1997: “Estrogen receptor  - tissue distribution and functional properties”.

184. NIEHS Conference on Estrogens in the Environment IV: Linking Fundamental Knowledge, Risk Assessment, and Public Policy, Arlington, Virgina, USA, July, 1997: “Hormone action of a new estrogen receptor: ER-“.

185. Gordon Research Conference on Hormone Action, New Hampshire, USA, July/August, 1997: “Characterization of a novel estrogen receptor”.

186. Gordon Research Conference on Hormonal Carcinogenesis, Tilton, USA, July/August, 1997: ”Novel insights into the mechanism of action of estrogens in the light of the discovery of a second estrogen receptor gene”.

187. 17th International Congress of Biochemistry and Molecular Biology, San Francisco, USA, August, 1997: “Ligand activated transcription factors in control of cytochrome P450”.

188. The fifth CFN Symposium, Effects of Toxicants on Gene Expression and Intracel-lular Signalling, Saltsjöbaden, Sweden, September, 1997: “Impact of environmental pollutants on nuclear receptors”.

189. Symposium on Phytoestrogen Research Methods, Chemistry, Analysis, and Biological Properties, Tucson, Arizona, USA, September, 1997: ”The estrogen -receptor and its interaction with phytoestrogens”.

190. Workshop on Estrogen Action, New Jersey, USA, October, 1997: ”Expression and Function of ER”.

191. XV Congrès de la Société Francaise d’Endocrinologie, Paris, France, October, 1997: ”Cloning, expression and role of a novel estrogen receptor”.

192. 9th International CBT Symposium, Steroid and Orphan Nuclear Receptors, Stockholm, Sweden, October, 1997: ”OR1 and PPAR - two major regulators of lipid metabolism”.

193. Molecular basis of sex hormone receptor function - New targets for intervention, Berlin, Germany, October, 1997: ”Estrogen receptor ”.

194. EMRC Workshop ”Crosstalk between steroid receptors and other transcription factors: molecular basis for immunomodulatory and anti-inflammatory effects of steroids”, Ottrott, Alsace, France, November, 1997: ”PPAR and OR-1: Two major regulators of lipid metabolism”.

195. Academy of Military Medical Sciences, Beijing, China, November, 1997: “Orphan receptors - a rapidly developing field with nutritional implications”.

196. Receptor Biology Roundtable, Center for Executive Education at Babson College, Massachusetts, USA, December, 1997: ”Estrogen receptor isoforms”.

197. Seminar at CIIT, North Carolina, USA, December, 1997: ”Nuclear receptors as mediators of chemical-induced toxic responses: Mechanism of peroxisome proliferator-activated receptor.

198. Distinguished lecturer seminar, NIEHS, Research Triangle Park, North Carolina, USA, December, 1997: ”The Estrogen Receptor Beta”.

199. AAAS Annual Meeting and Science Innovation Exposition, Philadephila, Pennsyl-vania, USA, February, 1998: Cochair at the symposium ”Manipulation of Science by Vested Interests: Money and Power versus Public Health”.

200. University of Colorado Health Sciences Center, Department of Pathology, Denver, USA, February, 1998: “Novel developments in nuclear receptors: postreceptor signalling and estrogen receptor ”.

201. Keystone Symposia on Breast and Prostate Cancer, Copper Mountain, Colorado, USA, February, 1998: “Mechanism of Action of Estrogen Receptor ”.

202. Tokyo Medical Association Meeting (Tokyo Society of Medical Science), Tokyo, Japan, February, 1998: “New developments in nuclear receptors: crosstalk, coactivators and orphan receptors”.

203. Symposium for Sex Difference and Similarity Society, Tokyo, Japan, February, 1998: “New developments in nuclear receptors: crosstalk, coactivators and orphan receptors”.

204. 1998 International Symposium on Biology of Prostate Growth, Bethesda, Maryland, USA, March, 1998: “Estrogen  receptor in prostate”.

205. Estrogens as initiators and promoters in breast and prostate cancer, Chantilly, Virginia, USA, March, 1998: “Structure and properties of estrogen receptor ”.

206. Keystone Symposia on Molecular & Cellular Biology, Nuclear Receptor Gene Family Conference, Lake Tahoe, Nevada, March/April, 1998: ”Estrogen receptor  predicted effects of estrogen”.

207. 2nd Congress of Molecular Medicine, Berlin, Germany, May, 1998: ”Biology of the novel estrogen receptor ER”.

208. IV European Congress of Endocrinology, Sevilla, Spain, May, 1998: ”Steroid receptors - New dimensions”.

209. 18th Blankenese Conference, Orphan receptors and novel ligands, Hamburg-Blankenese, Germany, May, 1998: ”OR-1 and peroxisome proliferator-activated receptors (PPAR) - two major regulators of lipid metabolism”.

210. Frontiers in Estrogen Action, Rio Grande, Puerto Rico, May, 1998: ”Signalling via estrogen receptor ”.

211. NFOG ’98, The Federation of Scandinavian Societies of Obstetrics and Gynecology, Århus, Denmark, May, 1998: ”Estrogen receptor : A new dimension in estrogen receptor research”.

212. Nordtox/NordEMS-98, The 5th Nordic Toxicology Meeting, Helsinki, Finland, May, 1998: “In vitro studies for understanding toxic mechanisms in vivo”.

213. European Federation of Endocrine Societies, 2nd Postgraduate Course in Molecular and Cellular Endocrinology, Turku, Finland, June, 1998: “The steroid/thyroid hormone receptor family”.

214. Laboratory Medicine 98, Turku, Finland, June, 1998: “Estrogen Receptor ”. Keynote lecture.

215. 3rd International Symposium on Women’s Health and Menopause, Risk Reduction Strategies - Improved Quality of Health, Florence, Italy, June, 1998: “Novel mechanisms of estrogen action” and ”Estrogen receptor  - a new hope for tissue specific HRT”

216. Xth Int. Congress on Hormonal Steroids, Québec, Canada, June, 1998: ”Estrogen receptor  - a new dimension in estrogen mechanism of action”. Keynote lecture.

217. Int. Congress of Toxicology, Paris, France, July, 1998: “PPAR activation and its consequences in experimental animals”.

218. Gordon Research Conference, New Hampshire, USA, July, 1998: “Expression and function of the new estrogen receptor: ER”.

219. Int. Congress of Pharmacology, München, Germany, July, 1998: ”Peroxisome proliferator activated receptor or PPAR”.

220. The Society for the Study of Reproduction, Texas, USA, August, 1998: “Physiology and molecular biology of estrogen receptor “. Keynote lecture.

221. NATO/FEBS Advanced Study Institute, International Summer School on Molecular Mechanisms of Transcellular Signalling: From Membrane Receptors to Trancription Factors, Spetsai, Greece, August, 1998: ”Coactivators and corepressors in nuclear receptor function” and ”Novel insights into the role of orphan nuclear receptors”.

222. European Teratology Society, Stockholm, September, 1998: “Basic concepts of hormone-receptor interactions”.

223. 3rd Int. Symp on Hormonal Carcinogenesis, Seattle, Washington, USA, September, 1998: “Estrogen receptor  - an important player in estrogen action”.

224. Estrogens and Human Health, Urbana, Illinois, USA, October, 1998: ”Estrogen receptors  and ”.

225. Sex-Hormones, Their Receptors and Biological Response, Louisville, Kentucky, USA, October, 1998: “New dimensions in estrogen action: ER”.

226. Steroid hormone action at the turn of the century. Four decades after puff induction by ecdysone, Marburg, Germany, October, 1998: ”Recent paradigm shifts in our understanding of estrogen signalling”.

227. Sex-Steroids and the Somatotropic Axis, La Playa, Naples, Florida, USA, October, 1998: ”Intracellular transacting signals”.

228. Breast and menopause, Wroclaw, Poland, October, 1998: “Estrogen receptor ”.

229. Nuclear Receptors - Minisymposium, Oslo, Norway, November, 1998: “Introduction into the nuclear receptor field”.

230. Sixth Annual Meeting of Japan Hormonal Steroid Society, Osaka, Japan, November, 1998: Keynote Lecture “Estrogen receptor  - a new dimension in estrogen mechanism of action”.

231. The first Märta Philipson Symposium in Pediatric Research, Stockholm, December, 1998: ”Estrogen receptor : Functional role for a new estrogen receptor in mam-malian development”.

232. AACR Special Conference on The Steroid Receptor Superfamily, Indian Wells, CA, USA, January, 1999: ”Estrogen receptor  - new exciting developments”.

233. 23rd International LOF-symposium on phyto-oestrogens, Gent, Belgium, January, 1999: ”The estrogen receptor  and its interaction with phytoestrogens”.

234. ILSI Health and Environmental Science Institute, Nassau, Bahamas, January, 1999: ”Nuclear Receptors”.

235. Endocrine Disruptors, Keystone, Lake Tahoe, USA, February, 1999: ”Properties, distribution & function of ER”.

236. Women’s Health Roundtable, Pasadena, USA, February, 1999: Estrogen receptors and other nuclear receptors”.

237. Estrogen and progesterone receptors and their ligands, Society for Gynecologic Investigation, Atlanta, USA, March, 1999: ”Estrogen Receptors: Alpha and Beta”.

238. The 4th Congress of the European Society for Gynecologic and Obstetric Investigation, Madonna di Campiglio, Italy, March, 1999: ”New dimensions in estrogen mechanism of action offer new hopes for therapy of diseases in the postmenopausal woman”.

239. Frontiers in Estrogen Action, Dana Point, California, USA, April, 1999: ”The nuclear receptors”.

240. 18th Joint Meeting of the British Endocrine Societies, Insulin resistance and cardiovascular disease: mechanisms and consequences, Bournemouth, UK, April, 1999: “Nuclear receptors involved in lipid metabolism: PPAR, ER, OR-1 and RLD-1”.

241. German Society of Endocrinology and German Society of Human Genetics, International Symposium on Breast and Prostate Cancer: Genes, Hormones and the Environment, Casle Elmau, close to Garmisch-Partenkirschen, Germany, April, 1999: ”Recent advances in our understanding of nuclear receptor action”.

242. Keystone Symposium on The PPARs: Transcriptional links to obesity, diabetes and cardiovascular disease, Keystone Resort, Colorado, April/May 1999: ”Downstream Modulators of PPAR Action”.

243. Endothelial derived vasoactive substances and free radicals in perinatal biology, NIH, Washington, May 1999: “Estrogen receptors - current concepts”.

244. Directors Seminar, NIH, Washington, May 1999: ”New dimensions in nuclear receptor signaling”.

245. EMBO Workshop, Steroid and Nuclear receptors, Villefranche, France, May 1999: “Biology and mechanism of action of estrogen receptor ”.

246. Int. Conference on Diet and Prevention of Cancer, Tampere, Finland, May/June 1999: “ER - an antioxidant receptor”.

247. Gordon Conference on Mammary Gland Biology, Hennecker, New Hampshire, USA, June 1999: ”ER: New excitement”.

248. XIIIth International Symposium on Gnotobiology, Djurönäset, Stockholm, June 1999: Steroid hormones, nutrients, nuclear receptors and coactivators – important players in control of gene expression”.

249. Nobelsymposium 113, “Estrogens and women’s health – benefit or threat?”, Karlskoga, Sweden, June/July 1999: “ER - a new paradigm in estrogen mechanism of action”.

250. Gordon Conference Research on Hormonal Carcinogenesis, New Hampshire, USA, August 1999: “Estrogen receptor : structure and function”.

251. 11th International Conference on Cytochrome P450, Sendai, Japan, August 1999: “Nuclear receptors – and update”.

252. Japanese Endocrine Disruptor Research Project, Tokyo, Japan, September 1999: “ER - a new dimension in understanding of estrogen action”.

253. 6th International Congress on Hormones and Cancer, Jerusalem, Israel, September 1999: “Recent advances in our understanding of the respective biological roles of estrogen receptor  and estrogen receptor ”.

254. Neuronal and cognitive effects of oestrogens, London, England, September 1999: “New horizons in estrogen mechanisms of action – estrogen receptor ”.

255. ECCO10 – the European Cancer Conference, Vienna, Austria, September 1999: “Estrogen receptor beta – new developments”.

256. International workshop: Estrogens and Male Reproduction (EMR), Isola Capo Rizzuto, Crotone, Italy, September 1999: “The role or estrogen receptor beta in male reproductive tissues”.

257. The 9th International Menopause Society World Congress on the Menopause, Yokohama, Japan, October 1999: “ER - new dimensions in estrogen mechanism of action”.

258. Svenska Mässan, “From Idea to Blockbuster”, Gothenburg, November 1999: “Novel nuclear receptors – a paradigm shift in drug development”.

259. SERMs: Implications for Prevention and Treatment of Breast Cancer, Philadelphia, USA, November 1999: “ER: More Surprises”.

260. National Institutes of Health, Menopause and Women’s Health – a Global Approach, USA, November 1999: “Physiological role of estrogen and estrogen receptors"”

261. 2nd Biennial International Meeting Flemish Gyneacological Oncology Group, Brussels, Belgium, December 1999: “New insights in ER research – The ER “.

262. International Symposium on Induction of Drug Metabolism From Molecular Mechanisms to Drug Approval, Stockholm, Sweden, December 1999: “Recent advances in our understanding of receptor mediated induction of drug-metabolizing enzymes”.

263. The Second International Symposium on: The Molecular Biology of Breast Cancer, Lillehammer, Norway, March 2000: “Estrogen receptors  and  in the rodent mammary gland”.

264. Congres Infertiliteit, gynaecologie en obstetrie anno 2000, Rotterdam, Netherlands, March 2000: “Estrogen receptors; modulation and clinical practise".

265. Estrogens: From research to clinical practice (Hormone-dependent cancers and menopause), Montpellier, France, March 2000: “ER - a paradigm shift in our understanding estrogen action”.

266. Keystone Symposia, Nuclear Receptors 2000, Steamboat Springs, Colorado, USA, March 2000: “ER - Surprises never end”.

267. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, Stockholm, Sweden, April 2000: “Roles of estrogen receptor  in the CNS”.

268. Nuclear Receptors in the Brain, Potential targets for therapeutic agents, Oegstgeest, The Netherlands, April 2000: Keynote lecture: “News and views on nuclear receptors”.

269. 4th Annual Frontiers in Estrogen Action, Palm Beach, Florida, USA, April 2000: Coorganizer and cochairman.

270. 27th European Symposium on Calcified Tissues, Tampere, Finland, May 2000: Keynotelecture: “Biological role of ER and ER“.

271. Estrogens: bone and vascular targets, Paris, France, May 2000: “Estrogen receptor  - a paradigm shift in understanding estrogen action”.

272. SFT seminar on Phytoestrogens, Stockholm, Sweden, May 2000: “A paradigm shift in our understanding of estrogen action”.

273. Swiss Bone and Mineral Society, Basel, Switzerland, May 2000: “ER - a new dimension in estrogen action”.

274. Int. Conf. on the Female Reproductive Tract, Frauenwörth, Germany, May 2000: “Estrogen receptor  - role in reproduction”.

275. Annual Meeting of the German Endocrine Society, München, Germany, June 2000: “New dimensions in estrogen receptors’ mechanisms of action”.

276. 6th Reisenburg International Symposium, Thyroid 2000: From bench to bedside, from gene to patient, Reisenburg, Germany, June 2000: “Nuclear receptors in control of lipid homeostasis”.

277. ASPET, Burroughs Wellcome Fund Lecture, Boston, USA, June 2000: “Estrogen receptor  - A paradigm shift in understanding estrogen action”.

278. 7th Nordic Nutrition Congress, Mariehamn, Åland, June 2000: “ Nutrients in control of gene regulation”.

279. Hormone-dependent Cancers and Nuclear Receptors, Saitama, Japan, June 2000: “Role of estrogen receptor  and  in steroid hormone-dependent tissues and cancers”.

280. International Meeting on Women’s Health and Menopause, NIH, Washington D.C., USA, July 2000: “Physiological Role of Estrogen and Estrogen Receptors”.

281. 14th Ecdysone Workshop, Rapperswil, Switzerland, July 2000: “On a paradigm shift in our understanding of estrogen mechanism of action: Discovery of estrogen receptor “.

282. VIth International Conference on Hormones, Brain and Behavior & The Society for Behavioral Neuroendocrinology, Madrid, Spain, August 2000: Keynote Lecture “Recent developments in our understanding of estrogen action: Estrogen Receptor “.

283. FEBS Advanced Study Institute, International Summer School on New dimensions in the regulation of gene expression, Spetses, Greece, August 2000: “Novel mechanisms in estrogen signalling” and “Nuclear receptor regulated lipid homeostasis”.

284. Third Annual Symposium on “Functional genomics – the human touch”, Gothenburg, Sweden, August 2000: “Potential of genomics for diagnosis and drug development – the example of the steroid receptor superfamily”.

285. EUROTOX 2000, XXXVIII European Congress of Toxicology, London, September, 2000: “The role of the ER in oestrogen mediated carcinogenesis”.

286. A Joint International Symposium arranged by the Center for Biotechnology (CBT), Karolinska Institutet and EUROSTERONE in collaboration with the Summer University of Southern Stockholm, “Nuclear Receptors in Health and Disease”, Huddinge, Sweden, September, 2000: “Estrogen receptor  - A paradigm shift in understanding estrogen action”.

287. Pannon Symposium, Tissue-selective estrogen action: from basic science to the clinical practice, Pécs, Hungary, September, 2000: Keynote lecture “Estrogen receptor-: A paradigm shift in understanding estrogen action”.

288. BioTech Forum, Älvsjömässan, Stockholm, Sweden, October, 2000: “Rational drug design based on steroid hormones and their receptors and the interaction between academic research and KaroBio AB”.

289. Cinquièmes Journées Européennes de la Sociéte Francaise de Gynécologie, Paris, France, October, 2000: “Estrogen receptors”.

290. Cardiovascular Disease and Hormone Replacement Therapy, IMS Workshop Royal Society of Medicine, London, U.K., October, 2000: “Estrogen receptors”.

291. E.hormone 2000 – the cutting edge of endocrine disrupter research, Tulane University, New Orleans, U.S.A., October, 2000: “Estrogen receptor  - a paradigm shift in our view on estrogen signaling and endocrine disruption”.

292. Keynote Lecture at Hormones and cancer 2000 and Aromatase 2000 and the 3rd generation, Port Douglas, Queensland, Australia, November, 2000: “Estrogen receptor – a paradigm shift in understanding estrogen action”.

293. Keynote Lecture at Garvan Symposium “Estrogens & Womens Health”, Sydney, Australia, November, 2000: “Mechanisms of estrogen action: the role of ERbeta”.

294. Keynote Lecture at Steroid receptor and cell signaling, Cincinnati, University of Cincinnati, USA, November, 2000: “Estrogen receptors and control of proliferation”.

295. European Medal Lecture. 191st Meeting of the Society for Endocrinology, London, U.K., November, 2000: “Estrogen receptor  - a paradigm shift in understanding estrogen action”.

296. 23rd Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, December, 2000: “ER and ER : “The Yin-Yang principle of estrogen action”.

297. 1st Meeting of the Network “Environmental Estrogens and their Effects in Health and Disease”, Athens, Greece, January, 2001: “The mechanism of action of estrogens – The role of ER “

298. Mayo Clinic, Rochester, USA, February, 2001: “Estrogen Receptor Beta – a Breakthrough in Understanding Estrogen Signaling”.

299. II International Symposium of the Portuguese Menopause Society, Menopause: Hormones and Cancer, Lisbon, Portugal, March, 2001: “Estrogen receptors and Breast Cancer”.

300. Disorders of the Prostate. Advances in Basic Mechanisms and the Implications for Clinical Management, Castres, France, March, 2001: “Oestrogen receptor beta knock out leads to hyperplasia in the ventral prostate”.

301. Experimental Biology 2001, The American Association of Immunologists, Orlando, Florida, USA, March/April, 2001: “Molecular aspects of estrogen receptors alpha and beta”.

302. 5th Annual Frontiers in Estrogen Action, County Clare, Ireland, April, 2001: “ER biology: New Frontiers”.

303. EMBO Workshop on Nuclear Receptor Structure and Function, Erice, Italy, May, 2001: “Novel aspects on estrogen signaling”.

304. 4th International Symposium on Women’s Health and Menopause, Washington DC, USA, May, 2001: “Estrogen signaling – New Paradigms”.

305. Eukaryotic Transcription: From mechanism to function, Turku, Finland, June, 2001: “Estrogen Receptors”.

306. Neuroendocrine Workshop on Hormones, Mood and Behavior, Breckenridge, Colorado, USA, June, 2001: “Estrogen receptor ”.

307. FASEB Summer Research Conference Program “Steroids and Bone”, Whitefish, Montana, USA, June, 2001: “ER-ER interplay in estrogen action”.

308. A Eurosterone Thematic Conference: Steroid signalling: New Frontiers, Edinburgh, Scotland, June, 2001: “New Frontiers in estrogen signalling”.

309. XIth International Congress on Genes, Gene Families and Isozymes; Stockholm, Sweden, June/July, 2001: “The nuclear receptor super gene family – developments and highlights”.

310. 17th Annual meeting of the European Society of Human Reproduction and Embryology, Lausanne, Switzerland, July, 2001: “Transgenic models in reproductive research”.

311. Bone and Tooth Society, Annual Meeting, Warwick, UK, July, 2001: “Regulation of transcription by different estrogen receptors”.

312. 15th Annual Symposium on The Long-Term Effects of Estrogen Deprivation, Bermuda, July, 2001: “Phenotypes of ER knockout mice”.

313. 7th International Summer School Behavioral Neurogenetics, Lake Erken, Norrtälje, Sweden, July, 2001: “A tale of two estrogen receptors”.

314. IMCB, Singapore, July, 2001: “New paradigms in estrogen signalling – estrogen receptor beta” and “LXRalfa and LXRbeta – two novel and important regulators of cholesterol homeostasis”.

315. Nuclear Receptors – Recent Developments, Oslo, Norway, August, 2001: “New paradigms in estrogen signalling”.

316. XXIII Congress of the European Society of Cardiology together with the 36th Annual General Meeting of the Association for European Paediatric Cardiology, Stockholm, September, 2001: “Update on estrogen receptors”.

317. The Charles Brenton Huggins Memorial Symposium, Chicago, USA, September, 2001: “ER-beta: A receptor with many faces”.

318. XXVIth European Symposium on Hormones and Cell Regulation, Mont Ste Odile, September, 2001: “On the role of estrogen receptor beta in reproduction” and “LXRs”.

319. Benzon Symposium No 48: Drug Metabolism Regulation and Importance, Copenhagen, September, 2001: “Molecular mechanisms of CYP induction”.

320. Medicon Valley BioConference 2001, Copenhagen, Denmark, September 2001: “Nuclear receptors as target for drug development – A scientifically and commercially hot area that may serve as a role model for a new paradigm in academic research”.

321. 8th ICEM, Shizuoka, Japan, October 2001: Plenary lecture “Nuclear receptor – environment interactions”.

322. Science in Japan Forum, Stockholm, October 2001: “Recent advances in understanding nuclear receptors”.

323. 3rd Biennial International Meeting of the Flemish Gynaecological Oncology Group, Endocrine treatment and prevention of breast and gynaecological cancers, Brussels, Belgium, November 2001: “The latest on ER beta in gynaecological and breast cancers”.

324. Workshop on Genomic vs non-genomic steroid action: Encountered or unified views, Madrid, Spain, December 2001: “The nuclear-receptor interacting proteins”.

325. First International Nuclear Receptor Meeting in Japan, Kyoto, Japan, March 2002: “An update on the biology of estrogen receptor beta”.

326. 2nd Annual Lectureship inWomen’s Health Research “From estrogen receptors to management of menopause”, Washington, USA, March 2002: “Estrogen receptor – A multifaceted player”.

327. Lecture at Chinese Academy of Medical Sciences, Beijing, China, April 2002: “Recent advances in our understanding of estrogen signalling pathways”.

328. 6th Annual Frontiers in Estrogen Action, Amelia Island, Florida, April 2002: “Update on the biology of ER”.

329. 7th Congress of the European Society of Contraception, Genova, Italy, April 2002: “Steroid receptors”.

330. Keystone meeting on Nuclear Receptor Superfamily, Snowbird, Utah, USA, April 2002: “On the role of ERbeta in the CNS”.

331. Swiss National Research Programme (NRP) 50 “Endocrine Disruptors”, Zürich, Switzerland, April 2002: “Steroid receptors and transcription mechanisms: action of endocrine disruptors”.

332. Hormones and Genome: Basic research towards improvement of diagnostic and therapeutic medicine, Blaubeuren/Ulm, Germany, May 2002: “New paradigms in estrogen signaling – ER as the Deus ex machina”.

333. Fourth Annual Symposium on Developmental & Molecular Toxicology, Development and Genetic Aspects of Breast Cancer, Madison, Wisconsin, USA, June 2002: “Estrogen signaling – a matter of thesis and antithesis”.

334. 10th World Congress on the Menopause, Plenary lecture, Berlin, Germany, June 2002: “Estrogen receptor – a multifacetted player”.

335. XIVth World Congress of Pharmacology, Plenary lecture, San Fransisco, USA, July 2002: “Estrogen receptors”.

336. Conférence du Centre de recherche, Quebec, Canada, July 2002: “Estrogen receptor  - an important and multifacetted player in estrogen signaling”.

337. National Cancer Centre, Tokyo, Japan, July 2002: “Novel aspects on estrogen signaling and hormone dependent cancer”.

338. 14th International Symposium on Microsomes and Drug Oxidations (MDO 2002), Sapporo, Japan, July 2002: “Crosstalk between PPAR and LXR: Two major regulators of lipid metabolism”.

339. Summer School/Bregenz 2002, “From genes via endocrine models to patients”, Bregenz, Austria, July 2002: “ER , ER and more” and “ED interactions with ER and ER”.

340. International Summer School on Neurotrophin and Nuclear Receptors: From Molecules to Behaviour, Lake Erken, Norrtälje, Sweden, August 2002: “Estrogen receptors: alpha and beta”.

341. Nuclear Receptors 2002 - A Joint International Symposium arranged by the Center for Biotechnology (CBT), Karolinska Institutet in collaboration with the Summer University of Southern Stockholm, Huddinge, Sweden, August 2002: “ERbeta as a regulator of cellular proliferation”.

342. The 5th International Congress of Neuroendocrinology, Bristol, U.K., August/September 2002: “Genomic and non-genomic actions of steroids”.

343. Nuclear receptors and disease, Göteborg, Sweden, September 2002: “Sterol homeostasis controlled by nuclear receptors”.

344. 30th Conference of the European Teratology Society in conjunction with the symposium Adverse effects of endocrine disruptors, Hannover, Germany, September 2002: “Mechanisms of endocrine signaling”.

345. 26th Congress of the Société Internationale d’Urologie, Stockholm, Sweden, September 2002: State-of-the-Art-Lecture: “The role of estrogen-receptor beta in control of prostate growth”.

346. ENEA 2002 Münich, 10th Meeting of the European Neuroendocrine Association, Münich, Germany, September 2002: “Estrogen receptors”.

347. European Respiratory Society, Annual Congress 2002, Stockholm, Sweden, September 2002: “Glucocorticoid receptors and cell signalling (overview talk)”.

348. Molecular mechanisms as targets in prostatic diseases, Liverpool, UK, September 2002: “The role and function of ER-beta in the development of prostate cancer”.

349. 2nd European Congress of Andrology, Malmö, Sweden, September 2002: “A novel endocrine pathway in the prostate, ER, AR, 5 -androstane-3, 17-diol, and CYP7B1, regulates prostate growth”.

350. International Society for the Study of Women’s Sexual Health, Annual Meeting 2002, Vancouver, Canada, October 2002: State of the Art Lecture, “New paradigms in understanding estrogen signaling”.

351. Tianjin TEDA Watson Biopark Development Conference, Tianjin, China, October 2002: “Recent advances in our understanding of nuclear receptor action”.

352. e.hormone 2002, New Orleans, USA, October 2002: “Environmental signals: Multiple receptors & multiple inputs”.

353. Women’s Health Special Interest Group (WHSIG), NIH; Washington, USA, November 2002: “Estrogen receptors – from molecular biology ot therapeutics”.

354. Burroughs Wellcome Fund Visiting Professorship In the Basic Medical Sciences, University of Texas Medical Brand School of Medicine, Houston, Texas, USA, November 2002: “A new paradigm in estrogen signaling provided by the dynamic interplay between ERalpha and ERbeta”.

355. Biomedicum Helsinki Seminars: Frontiers in Medicine, Helsinki, Finland, November 2002: “Nuclear receptors and regulation of cholesterol homeostasis”.

356. Fourth Amazon Project Conference, Innaovative Strategies and Perpectives in Cancer Care, Palermo, Italy, November 2002: “The novel estrogen receptor beta – possible implications for breast cancer”.

  1. British Pharmacological Society Wintermeeting, Nuclear receptors: targets for new therapies, Brighton, U.K., January 2003: “Oestrogen receptors”.

  2. Symposium Regulation of cell signalling by estrogens and phytoestrogens, McDowell Lecture in Physiology, London, U.K., January 2003: “Estrogens – how do they work?”.

  3. Distinguished Guest for 2003 in the Molecular and Cellular Biology Department at Baylor College of Medicine, Houston, Texas, U.S.A., February 2003: “A new look on estrogen signaling”.

  4. Ernst Schering Research Foundation, Workshop 46, New molecular mechanisms of estrogen action and their impact on future perspectives in estrogen therapy, Berlin, Germany, March 2003: “Novel functions of ER as revealed by studies of phenotypes of ER K.O.-mice”.

  5. International Group on Insulin Secretion, Novel Factors in the Regulation of -cell function, St. Jean-Cap-Ferrat, March 2003: Keynote Lecture, “Frontiers in nuclear receptors research”.

  6. On Target 2010: The Future of Medicines, Stockholm, Sweden, April 2003: “The academic research perspective”.

  7. Chairman at the 7th Annual Frontiers in Estrogen Action, The Homestead, Hot Springs, Virginia, April 2003.

  8. 6th European Congress of Endocrinology, Lyon, France, April 2003: Plenary Lecture, “Role of estrogen receptors: lessons from knock-out mice”.

  9. Calcified Tissue International, Rome, Italy, May 2003: Plenary Lecture, “Modulation of estrogen action by ER isoforms”.

  10. Novel approaches to treatment in hormone-sensitive breast cancer, London, U.K., May 2003: “Elucidation of ER function in breast cancer”.

  11. Utrecht Graduate School of Developmental Biology, Utrecht, The Netherlands, June 2003: “New paradigms in estrogen signaling”.

  12. 2nd Dutch Endo-Neuro-Psycho meeting, Doorwerth, The Netherlands, June 2003: Marius Tausk Lecture, “New paradigms in estrogen signaling”.

  13. EMBO Conference, Biology of Nuclear Receptors, Villefranche-sur-Mer (Nice), France, June 2003: “Antiproliferative actions of estrogen receptor ”.

  14. Special Symposium on estrogen receptors, Los Angeles, USA, June 2003: “Estrogen receptor-beta – A paradigm shift in understanding estrogen signaling”.

  15. Allosteric Mechanisms of Signal Transduction, Paris, France, June 2003: “Estrogen signaling – importance of conformational changes in estrogen receptor action”.

  16. European Code against cancer, Clinical Cancer Research in Europe, Milan, Italy, June 2003: “Oestrogen signaling and cancer”.

  17. Fourth International Symposium on Hormonal Carcinogenesis, Valencia, Spain, June 2003: “A novel mechanism for control of prostate growth”.

  18. Special FEBS 2003 Meeting on Signal Transduction; Signal transduction: from membrane to gene expression, from structure to disease, Brussels, Belgium, July 2003: Datta Lecture “Update on estrogen signaling”.

  19. 19th Ernst Klenk Symposium, Transcriptional and other regulatory mechanisms of lipid metabolism, Cologne, Germany, July 2003: “Some phenotypes of LXR KO mice”.

  20. HLSC 2nd event, Hormones and Genome, Molecular Mechanisms in Metabolic Diseases: Obesity, Diabetes Type 2, Lipid disorders and Atherosclerosis – Basic Science towards Clinical Application, Ulm, Germany, July 2003: “Some phenotypes of LXR KO mice”.

  21. Summer School on Endocrinology, Bregenz, Austria, July 2003: “Estrogen receptors and metabolic syndrome”.

  22. Nobel Conference No 40, Transcriptional control of lipid homeostasis, Stockholm, Sweden, August 2003: “LXR and control of lipid homeostasis”.

  23. FEBS Advanced Study Institute, International Summer School, From transcription to physiology: Regulation of gene expression and protein function in an integrated context, Spetses, Greece, September, 2003: “Mechanisms of estrogen action” and “Insight into the biology of estrogen and Liver X receptors by studying knock-out mice”.

  24. 8th Nottingham International Breast Cancer Conference, Nottingham, U.K., September, 2003: “Development and an overview of ER“.

  25. Lecture at the University of Mainz, Institute of Toxicology, Mainz, Germany, September, 2003: “New views on estrogen signaling”.

  26. Rudbeck seminars, Uppsala University, September, 2003: “New understanding of estrogen action”.

  27. The Endocrine Society: The Role of Nuclear Receptors in Cardiovascular Disease, San Diego, October, 2003: “Estrogens and the Immune System: Novel Lessons from ERalfa and ERbeta KO Mice”.

  28. The 2nd International Symposium of Gender Related Medicine at Centre of Gender Related Medicine, Karolinska Institutet, Stockholm, Sweden, October, 2003: “New paradigms of estrogen signalling – genderaspects”.

  29. Maturitas Master Class, Lisbon, Portugal, October 2003: “Steroid receptors” and “Specific alpha and beta ER-ligands”.

  30. International School of Medical Science, 117th Advanced Course on Signal Transduction and Communication in Cancer Cells, Erice, Italy, October 2003: “Estrogen Receptor Beta in Development and Cancer”.

  31. Eleventh Annual Nuclear Receptor Symposium, Nuclear Receptors: Discovery, Biology, and Therapy, Stevenage, U.K., October, 2003: “Novel views on estrogen signaling”.

  32. 13th Annual Meeting of the Dutch Society for Calcium and Bone Metabolism, Zeist, The Netherlands, October, 2003: “Estrogen signaling – a case of yin and yang”.

  33. The 6th U.S.- Taiwan Neuroscience Symposium, Estrogen actions in the brain, New Orleans, USA, November, 2003: “ERbeta in the nervous system”.

  34. Bengt E Gustafsson Symposium, Microbial Ecology in Health & Disease, Born germfree – microbial dependent, Stockholm, November 2003: “Metabolism”.

  35. Jensen Symposium, Nuclear Receptors and Endocrine Disorders, Cincinnati, USA, December 2003: “Estrogens and diseases of brain and the immune system”.

  36. Boosting Innovation from Research to Market, Bryssel, Belgium, December 2003: “Academy-industry interactions at the Novum Campus in Stockholm”
1   2   3   4   5   6   7   8


Curriculum vitae jan-Åke Gustafsson iconCurriculum vitae

Curriculum vitae jan-Åke Gustafsson iconCurriculum Vitae

Curriculum vitae jan-Åke Gustafsson iconCurriculum vitae

Curriculum vitae jan-Åke Gustafsson iconCurriculum vitae

Curriculum vitae jan-Åke Gustafsson iconCurriculum vitae

Curriculum vitae jan-Åke Gustafsson iconCurriculum vitae

Curriculum vitae jan-Åke Gustafsson iconCurriculum vitae

Curriculum vitae jan-Åke Gustafsson iconCurriculum vitae

Curriculum vitae jan-Åke Gustafsson iconCurriculum vitae

Curriculum vitae jan-Åke Gustafsson iconCurriculum Vitae

Разместите кнопку на своём сайте:

База данных защищена авторским правом © 2014
обратиться к администрации
Главная страница